Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant (BRAFmt) metastatic colorectal cancer (mCRC).
Authors
Vanessa Wong
Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
Vanessa Wong , Wei Hong , Sumitra Ananda , Catherine Dunn , Rachel Wong , Yat Hang To , Matthew E. Burge , Louise M. Nott , Jeanne Tie , Jeremy David Shapiro , Ross Jennens , Muhammad Adnan Khattak , Aflah Roohullah , Peter Gibbs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
DOI
10.1200/JCO.2022.40.4_suppl.047
Abstract #
47
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.
First Author: David Chan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2016 ASCO Annual Meeting
Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.
First Author: Thomas Aparicio